

Dear Editor and Reviewer:

We are truly grateful to yours and other reviewers' critical comments and thoughtful suggestions. Based on these comments and suggestions, we have made careful modifications on the original manuscript. We hope the new manuscript will meet your magazine's standard. Below you will find our itemized responses to the comments.

Yours sincerely.

Xue-Fei Tian and Piao Zheng

Response

Reviewer #1:

1. HCC is most common liver cancer in patients with chronic liver disease. Molecular classification of HCC reveals involvement of various genetic pathways for which till date there is no definitive management. The authors have used TCM in HCC in animals in this study. Though they have shown improvement in size and histological findings, it needs to be established in larger human trials with clinical relevance.

Answer: Thank you for your comment and advice. After the effectiveness of the animal models has been confirmed, the further establishment of large-scale human trials of clinical relevance and more in-depth research and exploration are also the goals of our next research. Thanks again to the reviewers for our research directions and suggestions.

Editor Office's Comments:

1. The abbreviation LF, HF, LM, HM, LFM, HFM, and ZD1839 should be explained in each figure.

Answer: Thank you for your reminding. We are very sorry for the omission here. We have added explanations of the abbreviations LF, HF, LM, HM, LFM, HFM, and ZD1839 in all figure legends.

2. For the network pharmacology part of the manuscript, the author should merge it without occupying 5 diagrams. Because this is not the author's main work.

Answer: Thank you for your advice. For the diagrams of the network pharmacology part of the manuscript, we have merged them into three.

3. The authors can consider adding EGFR-mediated signaling pathway inhibitors after drug treatment in cell experiments. This helps to explain the necessity of changing drug treatment.

Answer: Thank you for your advice. Our manuscript mainly proves the inhibitory effect of drug treatment on this molecule, so EGFR inhibitors are used as a positive control. On the basis of the research in this manuscript, in the next research work, we will use EGFR co-immunoprecipitation and the introduction of EGFR inhibitor group after drug treatment for further research and verification.

Company editor-in-chief:

1. I have reviewed the Peer-Review Report, the full text of the manuscript, and the relevant ethics documents, all of which have met the basic publishing requirements of the World Journal of Gastrointestinal Oncology, and the manuscript is conditionally accepted. I have sent the manuscript to the author(s) for its revision according to the Peer-Review Report, Editorial Office's comments and the Criteria for Manuscript Revision by Authors. Please provide decomposable Figures (in which all components are movable and editable), organize them into a single PowerPoint file.

Answer: Thank you for your help. We will organize the figures in the manuscript into a PowerPoint file as required and upload it to the corresponding location in the manuscript system.